I Know First Review: August 4th 2015

I Know First Review

The stocks selected here are the top performing stocks from I Know First: Biotech Stocks Package forecast for the last 3 moths found under the article titled Stock Market Algorithm: Up to 122.96% Return in 90 Days

This forecast is part of the Industry package, as one of I Know First’s quantitative investment solutions. The “I Know First Average” return for the long position was 19.66% over the 3 month period, a significant difference when comparing the S&P 500’s return of 0.88% over the same time period.

I Know First Review

Learn how to read the predictions: Instructions

Learn how to strategise with the forecast: Algorithmic Trading Strategies 

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.





Signal: 833.58

Predictability: 0.28

Return: -0.72%

OXiGENE, INC. (OXGN) is a clinical-stage biopharmaceutical company that develops novel therapeutics to treat numerous kinds of cancers. The Company is specialized in the development of vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumors.



Signal: 198.91

Predictability: 0.42

Return: 14.23%

Teva Pharmaceutical Industries Ltd. (TEVA) is an international pharmaceutical company that has its headquarters in Petah Tikva, Israel. The Company focuses mainly on generic drugs, and to a lesser extent on active pharmaceutical ingredients and proprietary pharmaceuticals. The company had a signal strength of 198.91 and a predictability indicator of 0.42. In accordance with the algorithm’s prediction, the stock price increased by 14.23%.

The Israeli company has announced that it will acquire Allergan’s generic unit for $40.5 billion. The Board of Directors of both companies approved the deal unanimously, and is expected to close in early 2016. Teva is convinced the acquisition will improve its supply chain, pipeline, and global revenue sources.



Signal: 90.07

Predictability: 0.35

Return: 122.96%

Exelixis, Inc. (EXEL) is a genomic-based discovery company located in South San Francisco, California. It focuses on the development of drugs, crop protection, and plant biotechnology.Exelelis is the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. The company had a signal strength of 90.07 and a predictability indicator of 0.35. In accordance with the algorithm’s prediction, the stock price increased by 122.96%.

Two weeks ago, the company’s shares surged roughly 50% after it announced positive results about its primary cancer drug Cometriq. It has been reported that the drug met its principal endpoint of improving progression-free survival for kidney cancer, in a pivotal late-stage trial, and their patients have shown significantly better results than those receiving Novartis’ Afinitor. As a consequence, Cometriq is expected to have a huge increase in sales if they can gain a regulatory approval as a second-line treatment for kidney cancer, whilst sales have been pretty poor so far.



Signal: 33.48

Predictability: 0.3

Return: 20.14%

Edwards Lifesciences Corp. (EW) provides products and technologies to treat structural heart disease and critically ill patients worldwide. It specializes in artificial heart valves and hemodynamic monitoring. The company had a signal strength of 33.48 and a predictability indicator of 0.3. In accordance with the algorithm’s prediction, the stock price increased by 20.14%.

On July 10th it was announced that Edwards Lifesciences agreed to acquire CardiAQ Valve Technologies for nearly $400 million. CardiAQ is a medical device company developing technologies for percutaneous mitral heart valve replacement. Following this news, stocks went up by 5%. Moreover, Edwards’ Q2 revenue of $616.8 million beats by $11.83 million.



Signal: 24.67

Predictability: 0.53

Return: -12.76%

Medivation, INC. (MDVN) is an American biopharmaceutical company headquartered in San Fransisco, California. It focuses on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options.



Signal: 50.89

Predictability: 0.51

Return: 1.91%

Bristol-Myers Squibb Company (BMY) is an American pharmaceutical company headquartered in New York City. The company manufactures prescription pharmaceuticals in several therapeutic areas. Its mission is to “discover, develop and deliver innovative medicines that help patients prevail over serious diseases.” The company had a signal strength of 50.89 and a predictability indicator of 0.51. In accordance with the algorithm’s prediction, the stock price increased by 1.91%.

The company has reported a YOY increase in revenues of 7%, which is meant to increase substantially going forward from Opdiva and Eliquis, and EPS of 0.53%, beating estimates by $0.17. Its very diversified portfolio for products makes the company a great name to continue to hold.



Signal: 13.46

Predictability: 0.13

Return: 37.19%

Intuitive Surgical, Inc. (ISRG) is an American corporation manufacturing robotic surgical systems, in particular the da Vinci Surgical System, which allows surgery to be performed using robotic manipulators. In 2003 the company merged with Computer Motion and now has over 1,242 systems installed worldwide. The company had a signal strength of 13.46 and a predictability indicator of 0.13. In accordance with the algorithm’s prediction, the stock price increased by 37.19%.

Intuitive Surgicalbeated Q2 earnings estimates with a reported YOY increase in revenues of 15.7% to $586.1 million, beats by $19.24 million, and an EPS of $4.57, beats by $0.59. CEO Gary Guthart explained that the growth of the products was particularly significant in key markets in Asia. Procedures grew strongly in China, and growth was solid in Japan as well as in Korea.



Signal: 12.98

Predictability: 0.36

Return: 3.60%

Roche Holding AG (ROG.VX) is a global health-care company headquartered in Basel, Switzerland, and the world’s largest bio-tech company. Founded in the late 19th century by Fritz Hoffmann-La Roche, the company was early on known for producing various vitamin preparations and derivatives. It is known for having produced the first antidepressant, iproniazid, by accident, and had produced various HIV tests and antiretroviral drugs. The company had a signal strength of 12.98 and a predictability indicator of 0.36. In accordance with the algorithm’s prediction, the stock price increased by 3.60%.

Being the largest maker of cancer drugs, Roche is looking to drive sales by lining up more new drugs, including an encouraging cancer immunotherapy it expects to launch by late 2016. The strategy has helped sales to increase in the first half a bit more than the expected 3%. On Thursday the share rose 1.1%, which has been described by Deutsche Bank as “modest, positive”.



Signal: 12.12

Predictability: 0.35

Return: -1.31%

AstraZeneca plc (AZN) is a British-Swedish multinational pharmaceutical and biologics company headquartered in London, UK. It has operations in more than 100 countries and is the world’s seventh-largest pharmaceutical company. Its portfolio includes products for major disease areas including, infection, and neuroscience.



Signal: 11.41

Predictability: 0.32

Return: 11.38%

AMGen Inc. (AMGN) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. It is the world’s largest independent biotechnology firm. Their products with the highest sales are drugs that are meant to prevent infections in patients that are undergoing cancer chemotherapy. The company had a signal strength of 11.41 and a predictability indicator of 0.32. In accordance with the algorithm’s prediction, the stock price increased by 11.38%.

Stocks rose to an all-time high following their report of an excellent beat-and-rise quarter. Amgen has a stable of good growth products. Their new drug Kyprolis, meant to treat myeloma, is annualizing at $480 million in sales, which is a good start. What remains to be seen is the long-awaited launch of the cholesterol-reducer Repatha, which could be significant to the future growth of the company.